JP5812541B2 - ８−ヒドロキシキノリン誘導体 - Google Patents

８−ヒドロキシキノリン誘導体 Download PDF

Info

Publication number
JP5812541B2
JP5812541B2 JP2013508559A JP2013508559A JP5812541B2 JP 5812541 B2 JP5812541 B2 JP 5812541B2 JP 2013508559 A JP2013508559 A JP 2013508559A JP 2013508559 A JP2013508559 A JP 2013508559A JP 5812541 B2 JP5812541 B2 JP 5812541B2
Authority
JP
Japan
Prior art keywords
group
methyl
quinolin
compound
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013508559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525473A5 (enExample
JP2013525473A (ja
Inventor
プシュカーシュ，ラースロー
サボー，チャバ
カニジャイ，イヴァン
ジュリシュ，マーリオ
マダーチ，ラモーナ
オージュバーリ，ベーラ
フェヘール，リリアーナ
タマーシュ，ガーボル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ubichem Kutato Korlatolt Felelossegu Tarsasag
Avidin Kft
Original Assignee
Ubichem Kutato Korlatolt Felelossegu Tarsasag
Avidin Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubichem Kutato Korlatolt Felelossegu Tarsasag, Avidin Kft filed Critical Ubichem Kutato Korlatolt Felelossegu Tarsasag
Publication of JP2013525473A publication Critical patent/JP2013525473A/ja
Publication of JP2013525473A5 publication Critical patent/JP2013525473A5/ja
Application granted granted Critical
Publication of JP5812541B2 publication Critical patent/JP5812541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2013508559A 2010-05-06 2011-05-06 ８−ヒドロキシキノリン誘導体 Active JP5812541B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1000243 2010-05-06
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Publications (3)

Publication Number Publication Date
JP2013525473A JP2013525473A (ja) 2013-06-20
JP2013525473A5 JP2013525473A5 (enExample) 2014-06-26
JP5812541B2 true JP5812541B2 (ja) 2015-11-17

Family

ID=89989711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508559A Active JP5812541B2 (ja) 2010-05-06 2011-05-06 ８−ヒドロキシキノリン誘導体

Country Status (21)

Country Link
US (1) US8871937B2 (enExample)
EP (1) EP2566849B1 (enExample)
JP (1) JP5812541B2 (enExample)
KR (1) KR101837974B1 (enExample)
CN (1) CN102985407B (enExample)
AU (1) AU2011256989B2 (enExample)
CA (1) CA2798419C (enExample)
CY (1) CY1122426T1 (enExample)
DK (1) DK2566849T3 (enExample)
EA (1) EA021026B1 (enExample)
ES (1) ES2761832T3 (enExample)
HR (1) HRP20192278T1 (enExample)
HU (2) HUP1000243A2 (enExample)
MX (1) MX337999B (enExample)
NZ (1) NZ603967A (enExample)
PL (1) PL2566849T3 (enExample)
PT (1) PT2566849T (enExample)
RS (1) RS59678B1 (enExample)
SI (1) SI2566849T1 (enExample)
SM (1) SMT201900710T1 (enExample)
WO (1) WO2011148208A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) * 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
WO2017066245A1 (en) * 2015-10-12 2017-04-20 Health Research, Inc. Methods for inducing apoptosis in cancer cells
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟（胺）基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives
WO2024073624A2 (en) * 2022-09-28 2024-04-04 The Research Foundation For The State University Of New York Antiproliferative betti bases and prodrugs thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015179A1 (en) 1997-09-25 1999-04-01 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AU2474399A (en) 1998-01-26 1999-08-09 Mitokor Mitochondria protecting agents for treating mitochondria associated diseases
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
DE60040397D1 (de) 1999-08-27 2008-11-13 Cytovia Inc Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
US6521617B2 (en) 2000-10-13 2003-02-18 The Johns Hopkins University Treatment of apoptotic cell death
WO2002048092A2 (en) 2000-12-15 2002-06-20 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
EP1414948B1 (en) 2001-07-10 2009-09-16 Biogen Idec Inc. Inhibition of apoptosis process and improvement of cell performance
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
EA200401070A1 (ru) 2002-02-13 2005-02-24 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы лечения сосудистых заболеваний
WO2005072295A2 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2004258801A1 (en) 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7462724B2 (en) 2005-11-15 2008-12-09 Abbott Laboratories Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
EP2139460A4 (en) * 2007-03-20 2011-09-07 Univ Brandeis COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED NEUROLOGICAL DISEASES
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
CA2687187A1 (en) 2007-05-25 2008-12-18 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
US10301265B2 (en) * 2008-05-28 2019-05-28 Virginia I. Roxas-Duncan Small molecule inhibitors of botulinum neurotoxins
EP2521551A4 (en) * 2010-01-06 2013-08-21 Errico Joseph P METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors

Also Published As

Publication number Publication date
HRP20192278T1 (hr) 2020-03-06
HU1000243D0 (en) 2010-06-28
CN102985407A (zh) 2013-03-20
US20130131096A1 (en) 2013-05-23
HUP1000243A2 (en) 2012-01-30
US8871937B2 (en) 2014-10-28
AU2011256989B2 (en) 2014-08-21
AU2011256989A1 (en) 2013-01-10
NZ603967A (en) 2014-06-27
SMT201900710T1 (it) 2020-01-14
DK2566849T3 (da) 2020-01-02
MX337999B (es) 2016-03-30
RS59678B1 (sr) 2020-01-31
EA201270787A1 (ru) 2013-04-30
HUE050886T2 (hu) 2021-01-28
CA2798419A1 (en) 2011-12-01
WO2011148208A1 (en) 2011-12-01
PT2566849T (pt) 2020-01-06
ES2761832T3 (es) 2020-05-21
KR20130029772A (ko) 2013-03-25
EA021026B1 (ru) 2015-03-31
PL2566849T3 (pl) 2020-03-31
KR101837974B1 (ko) 2018-03-13
SI2566849T1 (sl) 2020-02-28
EP2566849B1 (en) 2019-09-18
CY1122426T1 (el) 2021-01-27
JP2013525473A (ja) 2013-06-20
CA2798419C (en) 2021-01-05
EP2566849A1 (en) 2013-03-13
MX2012012883A (es) 2013-03-20
CN102985407B (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
CA2857405C (en) Phthalic hydrazide (phthalazine ketone) compounds as parp inhibitors and composition thereof
US8513433B2 (en) Small molecule inhibitors of PARP activity
JP5670266B2 (ja) フラザノベンゾイミダゾール
US20120135997A1 (en) Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
JP6693957B2 (ja) Ｈｄａｃ１／２阻害剤としてのピペリジン誘導体
KR20160132470A (ko) 피페리딘-다이온 유도체
WO2010126002A1 (ja) ヘテロ環スルホンアミド化合物を含有する医薬
JP5812541B2 (ja) ８−ヒドロキシキノリン誘導体
CN108530310A (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
JP2013532683A (ja) ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
JPWO2016148114A1 (ja) 酸化ストレス誘導神経細胞死抑制化合物
JP2018087173A (ja) 悪性脳腫瘍治療薬
US20130164218A1 (en) Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
KR20240035172A (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도
KR20240057820A (ko) 신규 피라졸로-옥소티아졸리딘 유도체 및 이를 포함하는 알칼리성 포스파타제 억제제
HK1197679A (en) Poly (adp-ribose) polymerase inhibitor
NZ715471A (en) Novel 2,5- or 2,6-disubstituted bicyclic heteroaryl compounds as modulators of gpr-119

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150914

R150 Certificate of patent or registration of utility model

Ref document number: 5812541

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250